Myriad Genetics Inc. and Pfizer Inc. announced a commercialization plan under an existing companion diagnostic agreement, in which Myriad is pursuing FDA approval for its BRACAnalysis CDx to be used as a companion diagnostic with Pfizer’s investigational PARP inhibitor, talazoparib.
As NCI employees and others at HHS were receiving notices of termination, national cancer organizations called on Congress “to restore stability to NIH.”
